The Cigna Group (CI) Market Cap & Valuation Ratios
The Cigna Group (CI) has a market cap of $81.1B, a trailing P/E of 12.7 and a price-to-sales ratio of 0.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CIThe Cigna GroupFollow CI — free
—
Price chart with a free account
- Market cap
- 81.1B
- P/E TTM
- 12.7
- Dividend yield
- 2.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
healthcare plans · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CI | 81 | 12.7 | 0.4 | 8.3 | 11.2% | +8% | 4% | 12% |
| UNH | 375 | 26.9 | 0.9 | 16.1 | 6.3% | +6% | 5% | 13% |
| CVS | 120 | 24.6 | 0.4 | 13.0 | 9.8% | +7% | 2% | 5% |
| ELV | 95 | 18.7 | 0.4 | 13.0 | 6.9% | +4% | 3% | 7% |
| HUM | 51 | 39.9 | 0.3 | 11.8 | 3.8% | +18% | 2% | 8% |
| CNC | 35 | — | 0.1 | — | — | +14% | -3% | -25% |
| MOH | 11 | — | 0.1 | 18.3 | 2.2% | -0.9% | 0.4% | 4% |
| OSCR | 9.6 | 18.5 | 0.1 | 2.2 | — | +43% | 4% | — |
| CLOV | 2.4 | — | 0.9 | — | 3.0% | +54% | -0.7% | -11% |
| PGNY | 2.2 | 31.5 | 1.5 | 16.8 | 8.0% | +6% | 9% | 22% |
| ALHC | 1.7 | 42.4 | 0.3 | 15.0 | 10.6% | +37% | 1% | — |
| Median of these 10 | 26.9 | 0.3 | 14.0 | 6.6% | +11% | 2% | 6% |
P/E 12.7 vs. a peer median of 26.9; EV/Sales 0.4 vs. 0.3. CI's own P/E sits at the 34th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesCNC and MOH and CLOV have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
The Cigna Group — questions
- What is The Cigna Group's market cap?
- $81.1B.
- What is The Cigna Group's P/E ratio?
- 12.7 on trailing twelve-month earnings to 2026-06-30.
- What is The Cigna Group's price-to-sales ratio?
- 0.3.
Every figure on this page comes from The Cigna Group's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.